Physician profile
Bruce D Hopper
NPI 1174577712
$722.76
in general payments reported to CMS, 2019-2025
9 companies · $50.03 in 2025
The $50.03 reported for 2025 was less than what a typical Addiction Medicine (Preventive Medicine) provider received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.50 · 2020: $115 · 2021: $43.91 · 2022: $122 · 2023: $136 · 2024: $216 · 2025: $50.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $268.95 | 2019-2024 | Epclusa |
| Indivior INC. | $190.84 | 2019-2024 | Sublocade |
| Alkermes, INC. | $87.90 | 2020-2024 | Vivitrol |
| Abbvie INC. | $77.48 | 2024 | |
| Braeburn INC. | $29.20 | 2023-2024 | Brixadi |
| Exact Sciences Corporation | $26.83 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $23.20 | 2025 | Rexulti |
| Hikma Pharmaceuticals USA | $18.36 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Hopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.